GGO Vergunningendatabase

Zoekcriteria

1. Rechtspersoon:
2. Uitgangs-organisme:
3. Procedure: Alle MA IG IM-MV IM-L
4. Dossiernummer:

1. Status: Alle Ter inzage Teruggetrokken Vergunning onherroepelijk In behandeling Besluit genomen Werkzaamheden gestart Kennisgeving niet ingestemd Besluit geweigerd Procedure afgerond Vergunning vernietigd Intrekkingsbesluit onherroepelijk Vergunning verleend
2. Datum vergunning vanaf:
3. Datum vergunning t/m:

1. Trefwoorden:

Zoekresultaat

IM-MV 20-002_000	Het Nederlands Kanker Instituut	Use of autologous patient-derived T cells enriched from peripheral blood mononuclear cells (PBMCs) and transduced with a gamma-retroviral self-inactivating (SIN) vector expressing a second generation chimeric antigen receptor (CAR) with specificity for the oncofetal antigen Claudin6 (CLDN6) under control of an internal promoter in patients suffering from CLDN6-positive malignancies	25-06-2020	Vergunning verleend
IM-MV 20-003_000	AMC	Clinical studies with MB‐CART2019.1, a product consisting of ex‐vivo lentiviral transduced T‐cells using a replication‐deficient lentiviral vector	17-06-2020	Vergunning verleend
IM-MV 20-004_000	UMCG	Clinical studies with MB-CART2019.1, a product consisting of ex-vivo lentiviral transduced T-cells using a replication-deficient lentiviral vector	17-07-2020	Vergunning verleend
IM-MV 20-005_000	Erasmus MC	Use of autologous patient-derived T cells enriched from peripheral blood mononuclear cells (PBMCs) and transduced with a gamma-retroviral self-inactivating (SIN) vector expressing a second generation chimeric antigen receptor (CAR) with specificity for the oncofetal antigen Claudin6 (CLDN6) under control of an internal promoter in patients suffering from CLDN6-positive malignancies	17-07-2020	Vergunning verleend
IM-MV 20-006_000	Erasmus MC	Clinical studies with MB-CART2019.1, a product consisting of ex-vivo lentiviral transduced T-cells using a replication-deficient lentiviral vector	21-07-2020	Vergunning verleend
IM-MV 20-007_000	LUMC	Clinical trials with Ad26COVS1	10-07-2020	Vergunning verleend
IM-MV 20-008_000	Universitair Medisch Centrum Utrecht	Clinical trials with Ad26COVS1	10-07-2020	Vergunning verleend
IM-MV 20-009_000	CHDR	Clinical trials with Ad26COVS1	10-07-2020	Vergunning verleend
IM-MV 20-011_000	Pharmaceutical Research Associates Group	Clinical trials with Ad26COVS1	10-07-2020	Vergunning verleend